8-K Announcements
6Material company update
Dec 29, 2025·SEC
Material company update
Dec 8, 2025·SEC
Material company update
Nov 25, 2025·SEC
Clearside Biomedical, Inc.(CLSD)Earnings, Financials & Key Ratios
CLSD•NASDAQ
Price updated May 25, 2026
AboutClearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.Show more
- Revenue$2M-79.8%
- EBITDA-$29M-15.7%
- Net Income-$34M-5.7%
- EPS (Diluted)-7.05+11.3%
- Gross Margin91.05%-4.8%
- EBITDA Margin-1722.12%-471.7%
- Operating Margin-1735.7%-474.7%
- Net Margin-2064.42%-422.8%
CLSD Key Insights
Clearside Biomedical, Inc. (CLSD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 2 (bottom 2%)
- ✗Sales declining 5.2% over 5 years
- ✗Shares diluted 19.4% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CLSD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CLSD Price & Volume
Clearside Biomedical, Inc. (CLSD) stock price & volume — 10-year historical chart
Loading chart...
CLSD Growth Metrics
Clearside Biomedical, Inc. (CLSD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-5.2%
3 Years-61.68%
TTM-56.78%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM18.45%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM23.94%
Return on Capital
10 Years-111.15%
5 Years-81.36%
3 Years-87.37%
Last Year-121.51%
CLSD Peer Comparison
Clearside Biomedical, Inc. (CLSD) competitors in Ophthalmology Therapies and Delivery — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 OCUL | 2.06B | 9.43 | -6.64 | -18.67% | -5.58% | -64.55% | 0.12 | |
 ADVM | 96.26M | 4.36 | -0.66 | -72.22% | -189.84% | 1.30 | ||
 RCKT | 365.8M | 3.35 | -1.67 | -70.79% | 0.09 | |||
 REPL | 841.41M | 10.19 | -3.32 | -102.69% | 0.18 | |||
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 AGIO | 2.03B | 34.16 | -4.80 | 48.03% | -6.4% | -34.11% | 0.05 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 ALDX | 118.23M | 1.96 | -3.50 | -0% | 0.35 |
Compare CLSD vs Peers
Clearside Biomedical, Inc. (CLSD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CLSD Income Statement
Clearside Biomedical, Inc. (CLSD) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 520K | 345K | 30K | 2.17M | 7.89M | 29.57M | 1.33M | 8.23M | 1.66M | 3.33M |
Revenue Growth % | - | -33.65% | -91.3% | 7143.33% | 263.28% | 274.65% | -95.51% | 519.89% | -79.77% | -56.78% |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 204K | 355K | 149K | 481K |
COGS % of Revenue | - | - | - | - | - | - | 15.37% | 4.32% | 8.95% | - |
Gross Profit | 520K▲ 0% | 345K▼ 33.7% | 30K▼ 91.3% | 2.17M▲ 7143.3% | 7.89M▲ 263.3% | 29.57M▲ 274.7% | 1.12M▼ 96.2% | 7.87M▲ 600.9% | 1.51M▼ 80.8% | 2.85M▲ 0% |
Gross Margin % | 100% | 100% | 100% | 100% | 100% | 100% | 84.63% | 95.68% | 91.05% | 85.55% |
Gross Profit Growth % | 1675.76% | -33.65% | -91.3% | 7143.33% | 263.28% | 274.65% | -96.2% | 600.89% | -80.75% | - |
Operating Expenses | 25.72M | 58.75M | 82.97M | 32.48M | 25.83M | 30.2M | 31.4M | 32.72M | 30.4M | 25.81M |
OpEx % of Revenue | 4945.77% | 17029.86% | 276583.33% | 1494.57% | 327.2% | 102.12% | 2366.24% | 397.7% | 1826.74% | - |
Selling, General & Admin | 6.26M | 9.7M | 14.68M | 16.82M | 10.76M | 11.66M | 11.77M | 11.87M | 11.81M | 12.67M |
SG&A % of Revenue | 1204.42% | 2811.59% | 48946.67% | 774% | 136.26% | 39.44% | 886.96% | 144.29% | 709.56% | - |
Research & Development | 19.45M | 49.05M | 68.29M | 15.66M | 15.07M | 18.54M | 19.63M | 20.85M | 18.59M | 13.22M |
R&D % of Revenue | 3741.35% | 14218.26% | 227636.67% | 720.57% | 190.94% | 62.68% | 1479.28% | 253.42% | 1117.19% | - |
Other Operating Expenses | 0 | -567K | 127K | 0 | 0 | 0 | 0 | 0 | 0 | -84K |
Operating Income | -25.2M▲ 0% | -58.41M▼ 131.8% | -82.94M▼ 42.0% | -30.3M▲ 63.5% | -17.93M▲ 40.8% | -627K▲ 96.5% | -30.28M▼ 4728.9% | -24.84M▲ 17.9% | -28.88M▼ 16.3% | -22.96M▲ 0% |
Operating Margin % | -4845.77% | -16929.86% | -276483.33% | -1394.57% | -227.2% | -2.12% | -2281.61% | -302.02% | -1735.7% | -689.76% |
Operating Income Growth % | -45.51% | -131.8% | -42.01% | 63.46% | 40.82% | 96.5% | -4728.87% | 17.94% | -16.25% | - |
EBITDA | -25.13M | -58.23M | -82.76M | -30.09M | -17.75M | -449K | -30.13M | -24.78M | -28.66M | -22.63M |
EBITDA Margin % | -4833.27% | -16877.1% | -275853.33% | -1384.86% | -224.92% | -1.52% | -2270.69% | -301.2% | -1722.12% | -679.78% |
EBITDA Growth % | -45.64% | -131.67% | -42.13% | 63.64% | 41% | 97.47% | -6610.91% | 17.77% | -15.66% | 7.56% |
D&A (Non-Cash Add-back) | 65K | 182K | 189K | 211K | 180K | 178K | 145K | 67K | 226K | 332K |
EBIT | -25.2M | -58.41M | -82.94M | -30.3M | -17.88M | 376K | -29.61M | -23.13M | -24.57M | -14.7M |
Net Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | -2.67M | -7.64M | -8.32M | -9.88M |
Interest Income | 0 | 0 | 0 | 1.03M | 335K | 0 | 669K | 1.72M | 1.46M | 701K |
Interest Expense | 0 | 0 | 0 | 1.03M | 335K | 0 | 3.34M | 9.36M | 9.78M | 10.58M |
Other Income/Expense | -684K | -567K | 127K | -466K | -275K | 1M | -2.67M | -7.64M | -5.47M | -2.32M |
Pretax Income | -25.88M▲ 0% | -58.98M▼ 127.9% | -82.82M▼ 40.4% | -30.77M▲ 62.8% | -18.21M▲ 40.8% | 376K▲ 102.1% | -32.95M▼ 8862.5% | -32.48M▲ 1.4% | -34.35M▼ 5.7% | -25.28M▲ 0% |
Pretax Margin % | -4977.31% | -17094.2% | -276060% | -1416.01% | -230.68% | 1.27% | -2482.82% | -394.91% | -2064.42% | -759.42% |
Income Tax | -65K | -182K | 127K | 0 | 0 | 0 | 0 | 0 | 0 | 715K |
Effective Tax Rate % | 0.25% | 0.31% | -0.15% | 0% | 0% | 0% | 0% | 0% | 0% | -2.83% |
Net Income | -25.88M▲ 0% | -58.98M▼ 127.9% | -82.82M▼ 40.4% | -30.77M▲ 62.8% | -18.21M▲ 40.8% | 376K▲ 102.1% | -32.95M▼ 8862.5% | -32.48M▲ 1.4% | -34.35M▼ 5.7% | -26M▲ 0% |
Net Margin % | -4977.31% | -17094.2% | -276060% | -1416.01% | -230.68% | 1.27% | -2482.82% | -394.91% | -2064.42% | -780.9% |
Net Income Growth % | -46.73% | -127.86% | -40.43% | 62.85% | 40.82% | 102.06% | -8862.5% | 1.4% | -5.75% | 18.45% |
Net Income (Continuing) | -25.88M | -58.98M | -82.82M | -30.77M | -18.21M | 376K | -32.95M | -32.48M | -34.35M | -26M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -29.55▲ 0% | -34.95▼ 18.3% | -40.35▼ 15.5% | -12.00▲ 70.3% | -5.85▲ 51.3% | 0.09▲ 101.6% | -8.25▼ 8830.2% | -7.95▲ 3.6% | -7.05▲ 11.3% | -4.97▲ 0% |
EPS Growth % | -36.81% | -18.27% | -15.45% | 70.26% | 51.25% | 101.62% | -8830.16% | 3.64% | 11.32% | 23.94% |
EPS (Basic) | -29.55 | -34.95 | -40.35 | -12.00 | -5.85 | 0.10 | -8.25 | -7.95 | -7.05 | - |
Diluted Shares Outstanding | 874.07K | 1.69M | 2.05M | 2.54M | 3.1M | 3.99M | 4.01M | 4.12M | 4.92M | 5.23M |
Basic Shares Outstanding | 874.07K | 1.69M | 2.05M | 2.54M | 3.1M | 3.9M | 4.01M | 4.12M | 4.92M | 5.23M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CLSD Balance Sheet
Clearside Biomedical, Inc. (CLSD) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 83.63M | 37.64M | 42.94M | 25.22M | 18.12M | 42.14M | 49.4M | 30.12M | 21.27M | 8.25M |
Cash & Short-Term Investments | 83.63M | 37.64M | 40.88M | 22.59M | 17.29M | 30.44M | 48.42M | 28.92M | 20.02M | 6.8M |
Cash Only | 34.82M | 9.22M | 8.04M | 22.59M | 17.29M | 30.44M | 48.42M | 28.92M | 20.02M | 6.8M |
Short-Term Investments | 48.81M | 28.42M | 32.84M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 10M | 0 | 170K | 507K | 266K |
Days Sales Outstanding | - | - | - | - | - | 123.42 | - | 7.54 | 111.21 | 85.71 |
Inventory | 0 | 0 | 0 | 0 | 0 | 921K | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 290K | 116K | 17K | 1.49M | 109K | 779K | 279K | 311K | 13K | 0 |
Total Non-Current Assets | 360K | 360K | 1.18M | 1.56M | 1.2M | 767K | 1.9M | 3.89M | 3.85M | 3.39M |
Property, Plant & Equipment | 94K | 885K | 790K | 1.2M | 944K | 607K | 1.87M | 3.87M | 3.82M | 3.36M |
Fixed Asset Turnover | 5.53x | 0.39x | 0.04x | 1.82x | 8.36x | 48.72x | 0.71x | 2.13x | 0.44x | 0.93x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 360K | 360K | 360K | 0 | 260K | 0 | 30K | 0 | 0 | 0 |
Other Non-Current Assets | -94K | -885K | 26K | 360K | 0 | 160K | 0 | 30K | 30K | 30K |
Total Assets | 84.81M▲ 0% | 40.49M▼ 52.3% | 44.12M▲ 9.0% | 26.78M▼ 39.3% | 19.32M▼ 27.8% | 42.9M▲ 122.0% | 51.3M▲ 19.6% | 34.02M▼ 33.7% | 25.13M▼ 26.1% | 11.64M▲ 0% |
Asset Turnover | 0.01x | 0.01x | 0.00x | 0.08x | 0.41x | 0.69x | 0.03x | 0.24x | 0.07x | 0.19x |
Asset Growth % | 302.82% | -52.26% | 8.96% | -39.31% | -27.84% | 122.04% | 19.58% | -33.69% | -26.14% | -192.04% |
Total Current Liabilities | 5.41M | 13.52M | 10.48M | 10.9M | 9.94M | 4.64M | 5.78M | 6.81M | 4.79M | 2.77M |
Accounts Payable | 2.59M | 5.38M | 6.87M | 1.28M | 2M | 941K | 1.05M | 2.21M | 1.45M | 796K |
Days Payables Outstanding | - | - | - | - | - | - | 1.88K | 2.27K | 3.56K | 1K |
Short-Term Debt | 0 | 3.2M | 556K | 1.33M | 991K | 0 | 349K | 364K | 0 | 0 |
Deferred Revenue (Current) | 160K | 140K | 0 | 5M | 5M | 0 | 205K | 75K | 0 | 0 |
Other Current Liabilities | 23K | 219K | 1.86M | 2.28M | 1.13M | 0 | 2.34M | 2.31M | 0 | 0 |
Current Ratio | 15.46x | 2.78x | 4.10x | 2.31x | 1.82x | 9.08x | 8.54x | 4.42x | 4.44x | 2.98x |
Quick Ratio | 15.46x | 2.78x | 4.10x | 2.31x | 1.82x | 8.88x | 8.54x | 4.42x | 4.44x | 2.98x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -918.04 |
Total Non-Current Liabilities | 7.59M | 8.01M | 10.02M | 4.72M | 616K | 288K | 34.91M | 43.12M | 59.19M | 62.82M |
Long-Term Debt | 7.59M | 4.81M | 9.42M | 3.82M | 0 | 0 | 33.98M | 41.99M | 51.77M | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 897K | 616K | 288K | 936K | 649K | 328K | 783K |
Deferred Tax Liabilities | -320K | -750K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 610K | 605K | 0 | 0 | 0 | 0 | 480K | 7.09M | 62.76M |
Total Liabilities | 13.15M | 19.08M | 20.5M | 15.62M | 10.56M | 4.93M | 40.7M | 49.93M | 63.98M | 65.59M |
Total Debt | 7.59M | 8.01M | 9.97M | 6.41M | 1.98M | 675K | 35.26M | 43M | 52.47M | 446K |
Net Debt | -27.24M | -1.22M | 1.93M | -16.19M | -15.31M | -29.76M | -13.16M | 14.08M | 32.45M | -6.36M |
Debt / Equity | 0.11x | 0.37x | 0.42x | 0.57x | 0.23x | 0.02x | 3.32x | - | - | -0.01x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.02x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.28x |
Interest Coverage | - | - | - | -29.31x | -53.36x | - | -8.87x | -2.47x | -2.51x | -1.39x |
Total Equity | 71.66M▲ 0% | 21.41M▼ 70.1% | 23.62M▲ 10.3% | 11.16M▼ 52.8% | 8.76M▼ 21.5% | 37.98M▲ 333.4% | 10.61M▼ 72.1% | -15.91M▼ 250.0% | -38.85M▼ 144.2% | -53.95M▲ 0% |
Equity Growth % | 295.47% | -70.12% | 10.3% | -52.76% | -21.46% | 333.36% | -72.07% | -250.01% | -144.19% | -382.06% |
Book Value per Share | 81.98 | 12.69 | 11.53 | 4.38 | 2.83 | 9.51 | 2.64 | -3.86 | -7.90 | -10.31 |
Total Shareholders' Equity | 71.66M | 21.41M | 23.62M | 11.16M | 8.76M | 37.98M | 10.61M | -15.91M | -38.85M | -53.95M |
Common Stock | 25K | 25K | 32K | 44K | 52K | 60K | 61K | 63K | 77K | 78K |
Retained Earnings | -65.25M | -124.22M | -206.89M | -237.66M | -255.87M | -255.49M | -288.44M | -320.92M | -355.27M | -373.96M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -13K | -8K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CLSD Cash Flow Statement
Clearside Biomedical, Inc. (CLSD) cash flow — operating, investing & free cash flow history
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -22.71M | -51.08M | -79.2M | -27.07M | -13.12M | -10.73M | -13.37M | -18.14M | -24.7M | -21.29M |
Operating CF Margin % | -4367.12% | -14806.67% | -264000% | -1245.65% | -166.2% | -36.29% | -1007.16% | -220.46% | -1484.25% | - |
Operating CF Growth % | -63.35% | -124.95% | -55.04% | 65.82% | 51.53% | 18.19% | -24.52% | -35.69% | -36.19% | -1111.61% |
Net Income | -25.88M | -58.98M | -82.82M | -30.77M | -18.21M | 376K | -32.95M | -32.48M | -34.35M | -26M |
Depreciation & Amortization | 65K | 182K | 189K | 211K | 180K | 178K | 145K | 67K | 226K | 332K |
Stock-Based Compensation | 1.31M | 3.36M | 4.79M | 4.61M | 3.6M | 5.05M | 4.88M | 4.2M | 4.51M | 3.33M |
Deferred Taxes | 65K | 181K | -748K | -52K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 439K | 211K | 266K | 230K | 188K | -998K | 3.32M | 9.36M | 6.59M | 2.97M |
Working Capital Changes | 1.29M | 3.95M | -874K | -1.3M | 1.12M | -15.34M | 11.24M | 720K | -1.68M | -1.92M |
Change in Receivables | 0 | 0 | 0 | 0 | 1.89M | -10.87M | 10.42M | -220K | -51K | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | -681K | 0 | 0 | 0 | 0 |
Change in Payables | 1.42M | 4.71M | -314K | -5.58M | 0 | 681K | 694K | 614K | -1.43M | -2.34M |
Cash from Investing | -49.14M | 20.12M | -3.76M | 32.92M | -55K | 0 | -246K | -1.78M | -638K | 9.3M |
Capital Expenditures | -3K | -306K | -88K | -25K | -55K | 0 | -246K | -1.78M | -977K | -453K |
CapEx % of Revenue | 0.58% | 88.7% | 293.33% | 1.15% | 0.7% | - | 18.54% | 21.6% | 58.71% | 13.61% |
Acquisitions | 0 | -20.12M | -660K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -360K | 20.12M | 660K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 86.39M | 5.36M | 81.78M | 8.7M | 7.87M | 23.78M | 31.33M | 414K | 16.44M | 4.91M |
Debt Issued (Net) | 1.53M | 0 | 1.7M | -5M | -4.35M | 0 | 30.64M | 0 | 0 | 961K |
Equity Issued (Net) | 84.83M | 5.06M | 79.56M | 13.64M | 11.96M | 23.28M | 695K | 1.67M | 16.39M | 3.53M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 31K | 305K | 515K | 52K | 258K | 499K | 0 | -1.25M | 47K | 418K |
Net Change in Cash | 14.54M▲ 0% | -25.6M▼ 276.1% | -1.18M▲ 95.4% | 14.55M▲ 1332.2% | -5.31M▼ 136.5% | 13.05M▲ 345.8% | 17.88M▲ 37.0% | -19.5M▼ 209.0% | -8.9M▲ 54.4% | -7.09M▲ 0% |
Free Cash Flow | -22.71M▲ 0% | -51.39M▼ 126.3% | -79.29M▼ 54.3% | -27.09M▲ 65.8% | -13.18M▲ 51.4% | -10.73M▲ 18.5% | -13.61M▼ 26.8% | -19.91M▼ 46.3% | -25.68M▼ 28.9% | -21.74M▲ 0% |
FCF Margin % | -4367.69% | -14895.36% | -264293.33% | -1246.8% | -166.9% | -36.29% | -1025.7% | -242.06% | -1542.97% | -652.96% |
FCF Growth % | -63% | -126.26% | -54.29% | 65.83% | 51.37% | 18.54% | -26.81% | -46.29% | -28.94% | -10.89% |
FCF per Share | -25.98 | -30.45 | -38.70 | -10.65 | -4.25 | -2.69 | -3.39 | -4.83 | -5.22 | -4.15 |
FCF Conversion (FCF/Net Income) | 0.88x | 0.87x | 0.96x | 0.88x | 0.72x | -28.55x | 0.41x | 0.56x | 0.72x | 0.84x |
Interest Paid | 0 | 0 | 0 | 0 | 524K | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CLSD Key Ratios
Clearside Biomedical, Inc. (CLSD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -147.9% | -126.73% | -367.79% | -176.96% | -182.83% | 1.61% | -135.63% | - | - | 55.47% |
Return on Invested Capital (ROIC) | -42.54% | -135.58% | -271.94% | -221.49% | - | -56.32% | -801.69% | - | - | 53.08% |
Gross Margin | 100% | 100% | 100% | 100% | 100% | 100% | 84.63% | 95.68% | 91.05% | 85.55% |
Net Margin | -4977.31% | -17094.2% | -276060% | -1416.01% | -230.68% | 1.27% | -2482.82% | -394.91% | -2064.42% | -780.9% |
Debt / Equity | 0.11x | 0.37x | 0.42x | 0.57x | 0.23x | 0.02x | 3.32x | - | - | -0.01x |
Interest Coverage | - | - | - | -29.31x | -53.36x | - | -8.87x | -2.47x | -2.51x | -1.39x |
FCF Conversion | 0.88x | 0.87x | 0.96x | 0.88x | 0.72x | -28.55x | 0.41x | 0.56x | 0.72x | 0.84x |
Revenue Growth | - | -33.65% | -91.3% | 7143.33% | 263.28% | 274.65% | -95.51% | 519.89% | -79.77% | -56.78% |
Related:CLSD Dividend History·CLSD Revenue History·CLSD Price History·CLSD P/E History·CLSD Financial Ratios·CLSD Institutional Holders
CLSD SEC Filings & Documents
Clearside Biomedical, Inc. (CLSD) SEC filings — annual & quarterly reports (10-K, 10-Q)
CLSD Frequently Asked Questions
Clearside Biomedical, Inc. (CLSD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Clearside Biomedical, Inc. (CLSD) reported $3.3M in revenue for fiscal year 2024.
Clearside Biomedical, Inc. (CLSD) saw revenue decline by 79.8% over the past year.
Clearside Biomedical, Inc. (CLSD) reported a net loss of $26.0M for fiscal year 2024.
Dividend & Returns
Clearside Biomedical, Inc. (CLSD) had negative free cash flow of $21.7M in fiscal year 2024, likely due to heavy capital investments.